Vasopressin: Nursing Drug Guide, Ischemia & Unit Dosing

U.S. labeling includes Vasopressin Injection, USP (for example 20 units/mL single-dose vials diluted before IV use) and branded Vasostrict presentations (including premixed sodium chloride bags). Strength, diluent, and whether chlorobutanol is present vary by vial size—verify the exact product with pharmacy.

Do not confuse vasopressin with desmopressin (DDAVP) or with catecholamine bags (norepinephrine, epinephrine, dopamine) in storage, MAR, and smart-pump libraries.

Per FDA prescribing information, vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines—commonly septic shock or post-cardiotomy vasodilatory shock when first-line pressors and volume are insufficient.

↔On a small screen, swipe or scroll sideways to see the full table.

Vasopressin binds V1 receptors on vascular smooth muscle, causing vasoconstriction and increased systemic vascular resistance. At therapeutic pressor doses it tends to decrease heart rate and cardiac output while raising mean arterial pressure—nurses must not equate a higher BP with improved perfusion.

Pressor effect peaks within about 15 minutes and fades within about 20 minutes after stopping the infusion per labeling. Steady-state plasma levels are reached after roughly 30 minutes of continuous infusion. Antidiuretic (V2) activity can contribute to water retention and hyponatremia during ICU use.

Individualize to hemodynamic targets. Titrate to the lowest effective units/min rate. All rates below are units/min per reviewed labeling (Amphastar Vasopressin Injection, USP).

Dilution (labeling Table 1)

Dilute 20 units/mL vial contents in 0.9% sodium chloride or D5W to 0.1 units/mL (2.5 mL [50 units] in 500 mL) when fluid restriction is not required, or 1 unit/mL (5 mL [100 units] in 100 mL) when fluid restriction is required. Discard unused diluted solution after 18 hours at room temperature or 24 hours refrigerated.

Weaning

After target blood pressure is maintained for 8 hours without catecholamines, taper vasopressin by 0.005 units/min every hour as tolerated per labeling.

Pediatrics: Safety and effectiveness in pediatric vasodilatory shock have not been established per labeling.

Pregnancy: Clearance increases in later trimesters—dose adjustments may be needed; labeling warns vasopressin may produce tonic uterine contractions.

Missed dose: Not applicable to continuous infusion—if interrupted, verify line patency and prescriber direction; taper when discontinuing and monitor for reversible diabetes insipidus after stop.

Pretreatment checks

• Confirm labeled indication: vasodilatory shock with hypotension despite fluids and catecholamines
• Perform medication reconciliation for concurrent catecholamines, SSRIs/TCAs, haloperidol, lithium, demeclocycline, indomethacin, and other drugs affecting pressor or sodium balance
• Verify pharmacy dilution (0.1 vs 1 unit/mL); program pump in units/min with independent double-check—not mcg/min
• Establish central or large-vein access when possible; follow central line care
• Document baseline blood pressure, rhythm, sodium, and urine output
• Inspect solution for particulates and discoloration before dilution and administration
• Screen for allergy to 8-L-arginine vasopressin or chlorobutanol when present in the product

Contraindications

• Known allergy or hypersensitivity to 8-L-arginine vasopressin
• Known allergy or hypersensitivity to chlorobutanol in products that contain it (for example some 1 mL single-dose vials)—not specified in all formulations

Warnings (labeling)

• Can worsen cardiac function: Decreased cardiac index may occur—do not up-titrate based on BP alone
• Reversible diabetes insipidus after discontinuation: Polyuria, dilute urine, hypernatremia—monitor electrolytes and urine output after stop
• Ischemia: Coronary, mesenteric, skin, and digital ischemia reported—assess abdomen and extremities
• Hyponatremia: Common adverse reaction—trend sodium with fluid balance

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Incompatibilities: Not specified in the reviewed prescribing information for vasopressin injection—follow pharmacy compatibility resources and institutional policy.

Route: Intravenous continuous infusion only. Dilute before use per labeling—20 units/mL concentrate to 0.1 units/mL or 1 unit/mL. Some premixed products (for example certain Vasostrict bags) may not require further dilution—follow the specific product label.

• Infuse through a large vein or central line; assess site frequently for extravasation and ischemic skin changes
• Use IV infusion pump setup programmed in units/min with verified concentration and mL/hour
• Never bolus undiluted 20 units/mL concentrate
• Discard diluted solution per stability limits (18 h room temperature / 24 h refrigerated per labeling)
• Store unrefrigerated vials per manufacturer temperature guidance until removal from cold chain

• Improved mean arterial pressure when vasodilatory shock is the target disorder
• Ability to reduce catecholamine doses after MAP stabilizes—labeling describes tapering vasopressin after 8 hours without catecholamines
• Urine output and perfusion may improve when renal and splanchnic flow recover—reassess if oliguria persists despite acceptable BP
• Lactate and clinical perfusion should trend favorably when shock resolves—rising lactate with stable MAP suggests ischemia or inadequate resuscitation
• Heart rate may fall as cardiac index decreases—evaluate perfusion and output, not rate alone

Escalate immediately for ischemia, dangerous rhythm changes, severe hyponatremia symptoms, or pump programming errors.

• Cool, mottled, or painful fingers/toes; absent distal pulses—possible digital ischemia
• Severe abdominal pain, bloody stools, or peritonitis signs—possible mesenteric ischemia
• Chest pain or new ischemic ECG changes—possible coronary ischemia
• Extravasation with blanching, coolness, or pain at the IV site—stop infusion and follow institutional vesicant/extravasation protocol
• Confusion, seizure, or worsening headache with falling sodium—hyponatremia or water retention
• Sustained palpitations or ventricular tachyarrhythmias including Torsade de Pointes (overdose labeling)

Labeling states the most common adverse reactions are decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital). Additional reported events include distal limb ischemia, mesenteric ischemia, myocardial ischemia, acute renal insufficiency, and ischemic skin lesions.

↔On a small screen, swipe or scroll sideways to see the full table.

Overdosage per labeling manifests as vasoconstriction of peripheral, mesenteric, and coronary beds and as hyponatremia. Less commonly: ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and nonspecific gastrointestinal symptoms.

Management (labeling)

• Stop or reduce infusion—direct hemodynamic effects resolve within minutes of withdrawal per labeling
• Monitor blood pressure, rhythm, perfusion, and sodium until stable
• Correct hyponatremia and fluid imbalance per prescriber and institutional protocol

Systemic antidote: Not specified in the reviewed prescribing information beyond discontinuation and supportive care.

Extravasation: Not specified in the reviewed Amphastar vasopressin injection label—follow institutional vesicant/extravasation protocol; ischemic injury to extremities and bowel is a labeled systemic risk.

• Vasopressin vs desmopressin (DDAVP)—completely different indications and dosing; desmopressin is not a continuous units/min shock drip
• Vasopressin vs norepinephrine / epinephrine / dopamine—triple-check MAR, bag label, and pump library; units/min vs mcg/min vs mcg/kg/min
• 0.1 units/mL vs 1 unit/mL bags—tenfold concentration error if the wrong dilution is hung
• units/min vs mL/hour alone—independent double-check rate, concentration, and mL/hour every new bag
• Undiluted 20 units/mL vial—never connect concentrate directly to the patient
• Verbal “pressor” orders—require read-back with drug name, indication, units/min, and concentration

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous cardiac rhythm and frequent blood pressure with perfusion assessment
• Serum sodium and basic metabolic panel trends—hyponatremia is a labeled common reaction
• Urine output, capillary refill, and extremity perfusion
• Cardiac index or clinical surrogates when available—labeling warns of decreased cardiac output; monitor for arrhythmia
• Serial lactate during shock resuscitation when already trending perfusion
• IV site for extravasation and localized ischemia
• After discontinuation: urine osmolality/specific gravity pattern, sodium, and signs of reversible diabetes insipidus

Document

• Shock type (septic vs post-cardiotomy), starting units/min, concentration, and response after each titration
• Fluid and catecholamine therapy given before and during vasopressin
• Sodium values and fluid balance with each rate change
• Abdominal and peripheral perfusion examinations when ischemia is a concern

• This medicine supports blood pressure during severe shock when other IV medicines and fluids are not enough—only the care team adjusts the pump
• Report new belly pain, chest pain, headache, confusion, or numb/cold fingers or toes immediately—these can signal ischemia or low sodium
• Expect frequent blood pressure checks and lab draws for sodium while the infusion runs
• The drip will be lowered slowly in small steps—not stopped suddenly—per your care plan
• After the medicine is stopped, you may pass large amounts of dilute urine for a time—the team will watch sodium and fluids

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for vasopressin using a tabbed ICU case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, sodium/perfusion trend interpretation, matrix urgency sorting, units/min safety judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.